Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

January 7, 2024

https://www.globenewswire.com/news-release/2024/01/07/2805011/32920/en/Exagen-Inc-Announces-Select-Preliminary-Full-Year-2023-Results-and-Reaffirms-Guidance.html

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.

Read more at globenewswire.com

Related news for (XGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.